ESPR

Esperion Therapeutics, Inc.

2.63 USD
+0.02 (+0.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Esperion Therapeutics, Inc. stock is up 23.47% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 10 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Jan 16:51 21 Jun, 2024 3.00 CALL 1614 3529
19 Jan 20:43 16 Feb, 2024 2.00 PUT 5000 498
22 Jan 14:45 17 Jan, 2025 2.00 CALL 250 20154
22 Jan 14:45 17 Jan, 2025 2.00 CALL 900 20154
22 Jan 19:45 17 Jan, 2025 1.00 CALL 200 2347
31 Jan 20:18 17 Jan, 2025 1.00 CALL 500 2103
06 Feb 16:28 21 Jun, 2024 5.00 PUT 300 109
08 Feb 19:47 19 Apr, 2024 3.00 CALL 1300 211
14 Feb 17:17 17 Jan, 2025 2.00 CALL 200 20082
22 Feb 19:06 17 Jan, 2025 1.00 CALL 500 2540

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.